The availability of new antiviral agents opens the way for increasing GP involvement in the management of hepatitis C
The new direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infections became available on the Pharmaceutical Benefits Scheme in March 2016. In September 2016, already over 10% of the estimated 230 500 Australians with chronic HCV infection had been treated.1 While such rapid uptake was unanticipated, it may represent the low-hanging fruit of the HCV epidemic: patients already enlisted in tertiary clinics waiting for treatment. From an epidemiological perspective, the remaining untreated patients may fall under the radar of tertiary-based clinics. If Australia is to capitalise on the opportunities of universal access to DAA therapies, it will require the concerted efforts of general practitioners to improve rates of diagnosis, assessment, treatment and follow-up in the community.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. The Kirby Institute. Initiations of new treatment for chronic hepatitis C during March to September 2016. Monitoring hepatitis C treatment uptake in Australia 2017; Issue 6, February, 2017. Sydney: The Kirby Institute, University of New South Wales Sydney. https://kirby.unsw.edu.au/sites/default/files/kirby/report/Monitoring-hep-C-treatment-uptake-in-Australia_Iss6-FEB17.pdf (accessed May 2017).
- 2. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual surveillance report 2016. Sydney: Kirby Institute, 2016. https://kirby.unsw.edu.au/sites/default/files/kirby/report/SERP_2016-Annual-Surveillance-Report_UPD170116.pdf (accessed May 2017).
- 3. Pharmaceutical Benefits Scheme. General statement for drugs for the treatment of hepatitis C. http://www.pbs.gov.au/info/healthpro/explanatory-notes/general-statement-hep-c (accessed May 2017).
- 4. Thompson AJV. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust 2016; 204: 268-272. <MJA full text>
- 5. Wade AJ, Veronese V, Hellard ME, Doyle JS. A systematic review of community based hepatitis C treatment. BMC Infect Dis 2016; 16: 202.
- 6. Mina MM, Clark PJ, Beasley HM, et al. Enhancing hepatitis C treatment in the custodial setting: a national roadmap. Med J Aust 2014; 200: 15-16. <MJA full text>
- 7. Arora S, Kalishman S, Thornton K, et al. Expanding access to HCV treatment – Extension for Community Healthcare Outcomes (ECHO) Project: disruptive innovation in specialty care. Hepatology 2010; 52: 1124-1133.
- 8. Keogh K, Clark P, Valery PC, et al. Use of telehealth to treat and manage chronic viral hepatitis in regional Queensland. J Telemed Telecare 2016; 22: 459-464.
- 9. Lobo R, Mascarenhas L, Worthington D, et al. Evaluation of the regional nurse-supported hepatitis C shared care program in Western Australia: a mixed methods study. BMC Health Serv Res 2015; 15: 399.
- 10. Queensland Injectors Health Network. Hepatitis C Treatment and Management Program. https://www.quihn.org/hepatitis-c-treatment-and-management-program (accessed May 2017).
- 11. Jackson C, Askew D. Is there a polyclinic alternative acceptable to general practice? The ‘Beacon’ practice model. Br J Gen Pract 2008; 58: 733.
- 12. Hepworth J, Bain T, van Driel M. Hepatitis C, mental health and equity of access to antiviral therapy: a systematic narrative review. Int J Equity Health 2013; 12: 92.
- 13. Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (January 2017). Melbourne: Gastroenterological Society of Australia, 2017. https://www.asid.net.au/documents/item/1208 (accessed May 2017).
- 14. Hopwood M, Treloar C. Under the watchful eye of ‘a benevolent dictator’. Aust Fam Physician 2013; 42: 900-903.
No relevant disclosures.